Treatment of steroid-resistant acute graft-versus-host disease with rabbitantithymocyte globulin

Acute graft-versus-host disease (A-GVHD) is a life-threatening complication of allogeneic stem cell transplantation (SCT), and primary therapy consist s of high-dose corticosteroids. Patients who fail to respond adequately to corticosteroids require salvage treatment, with anti-T cell antibodies bein g the most commonly utilized group of agents. We report our institution's e xperience treating steroid-resistant GVHD in 36 adult patients (median age 39 years, range 24-55) with a rabbit anti-thymocyte globulin product (thymo globulin). Eleven patients had undergone sibling SCT (10 histocompatible, 1 one-antigen mismatched) and 25 patients had received unrelated donor bone marrow (17 matched, 8 one-antigen mismatched); 32 patients (89%) had grade III or IV A-GVHD. Thymoglobulin was administered in two different regimens; group 1 patients (n = 13) received 2.5 mg/kg/day X 4-6 consecutive days wi th maintenance of all other immunosuppressives. Group 2 patients (n = 21) w ere given the same dose of thymoglobulin on days 1, 3, 5, and 7 with discon tinuation of cyclosporine for 14 days, during which the corticosteroid dose was held at 23 mg/kg/day. Two patients had severe adverse reactions to thy moglobulin (hypoxemia and hypotension) and could not complete treatment, ho wever, in the other patients, aside from transient leukopenia (25%) and and hepatic dysfunction (25%), the antibody preparation was well tolerated. Of the 34 evaluable patients, 13 patients had a complete response (38%) and 7 patients (21%) had a partial response, for an overall response rate of 59% . Response rate was higher in group 1 patients (77%) compared to group 2 pa tients (48%), (p = 0.15); skin GVHD was more responsive (96% of patients) t han gut GVHD (46% of patients) or hepatic GHVD (36% of patients). Opportuni stic infections were a significant complication, with 11 patients developin g systemic fungal infections and 9 patients serious viral infections; there were seven episodes of bacteremia following thymoglobulin treatment and on e fatal protozoal infection. There were 9 patients (25%) who developed post -SCT lymphoproliferative disorder (PTLD) and 4 patients who had a relapse o f underlying primary malignancy; none of these patients survived. Of the 36 patients entered on the study, only 2 patients (6%) survive, at 15(+) and 34(+) months post-unrelated donor SCT. Although thymoglobulin is associated with an impressive response rate when administered for advanced steroid-re sistant GVHD, long-term survival is uncommon, even in responders, primarily due to the high risk of developing either an opportunistic infection or a PTLD.